Opdivo is an immunotherapy cancer treatment that people receive as an intravenous infusion. Because doctors usually administer Opdivo as an outpatient treatment, Medicare Part B covers 80% of the costs. Medicare beneficiaries pay 20% or less of the price after they have met the deductible.
Full Answer
How can I get help with the cost of Opdivo?
Help patients find transportation, medical services, care at home, and other local healthcare-related resources. BMS Access Support ® can help identify financial assistance programs for eligible patients who have been prescribed OPDIVO and who need help managing the cost of treatment. The appropriate program will depend on the patient's coverage.
What is the prevalence of diabetes in Opdivo monotherapy?
In patients receiving OPDIVO monotherapy, diabetes occurred in 0.9% (17/1994) of patients, including Grade 3 (0.4%) and Grade 2 (0.3%), and 2 cases of diabetic ketoacidosis.
Does Medicare cover Opdivo?
Medicare covers the cost of cancer treatments, including Opdivo. Doctors use this medication to treat cancers such as melanoma, lung cancer, Hodgkin lymphoma, and liver cancer. The National Institutes for Health (NIH) report 1.8 million new cancer cases in the United States in 2020.
What are the possible side effects of Opdivo?
The most frequent serious adverse reactions reported in ≥2% of patients receiving OPDIVO were urinary tract infection, sepsis, diarrhea, small intestine obstruction, and general physical health deterioration. In Checkmate 142 in MSI-H/dMMR mCRC patients receiving OPDIVO with YERVOY (n=119), serious adverse reactions occurred in 47% of patients.
Is Opdivo a Part B drug?
Opdivo is a specialty immunotherapy medication used to treat certain cancers. Medicare Part B will cover Opdivo infusions in outpatient centers or your doctor's office.
How much does Opdivo and Yervoy cost?
The combination of Yervoy (ipilumumab) and Opdivo (nivolumab) will cost more than $250,000 per year. Bristol-Myers Squibb is also testing the Yervoy/Opdivo combo for treatment of lung cancer.
Is Opdivo expensive?
The cost for Opdivo intravenous solution (10 mg/mL) is around $1,247 for a supply of 4 milliliters, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.
What are the most common side effects of Opdivo?
The most common side effects of OPDIVO, when used in combination with YERVOY and chemotherapy, include: feeling tired; pain in muscles, bones, and joints; nausea; diarrhea; rash; decreased appetite; constipation; and itching.
How much longer can you live with Opdivo and Yervoy?
With a minimum follow-up of 6.5 years, median overall survival (OS) was 72.1 months with Opdivo plus Yervoy (95% CI: 38.2-NR), the longest reported median OS in a Phase 3 advanced melanoma trial, 36.9 months with Opdivo (95% CI: 28.2-58.7) and 19.9 months with the Yervoy group (95% CI: 16.8-24.6).
When should I stop using Opdivo?
If your doctor confirms you had a serious allergic reaction to Opdivo, they'll stop your Opdivo treatment and decide if another cancer treatment is right for you.
What is the success rate of Opdivo?
Of patients still alive and part of the current analysis, 77% of those who received the combination of Opdivo + Yervoy, 69% of those who received just Opdivo, and 43% of those who received Yervoy have been off treatment and never received subsequent systemic therapy for melanoma.
Does insurance pay for immunotherapy?
Immunotherapy trains your immune system to treat different types of cancer and prevent allergic reactions. Private health insurance, Medicare, and Medicaid may cover immunotherapy. Patient assistance programs and other financial support could also help you pay for immunotherapy.
How much does nivolumab cost per month?
Of note, the monthly price of nivolumab-ipilimumab combination therapy would have to be reduced from $26 425 to $5058 (an 80.9% reduction) to be cost-effective compared with chemotherapy.
How long does immunotherapy extend life?
Generally, at 2 years, if patients have done well on therapy, and you have 2 years of ongoing disease control, in most patients we are stopping at 2 years and then monitoring them.
Does Opdivo shrink tumors?
Nivolumab (Opdivo) helps shrink tumors, helps patients with advanced melanoma to live longer and decreases the risk of the melanoma coming back after surgery. It is also approved for adjuvant therapy.
Can Stage 4 melanoma be cured with immunotherapy?
Immunotherapy is used to treat advanced (stage 4) melanoma, and it's sometimes offered to people with stage 3 melanoma as part of a clinical trial. Immunotherapy uses medicine to help the body's immune system find and kill melanoma cells.
How much does nivolumab cost per month?
Of note, the monthly price of nivolumab-ipilimumab combination therapy would have to be reduced from $26 425 to $5058 (an 80.9% reduction) to be cost-effective compared with chemotherapy.
What is the cost of ipilimumab?
Adjuvant Ipilimumab for Melanoma—The $1.8 Million per Patient Regimen. We are all now used to hearing the broken record berating the high prices of cancer drugs.
What does Opdivo and yervoy treat?
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat people with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma). It is not known if OPDIVO is safe and effective in children younger than 18 years of age.
What is the most common type of immunotherapy?
Naked monoclonal antibodies are the most common type used in cancer treatment. They're called naked because they're unattached to anything. These antibodies boost your immune system's response against the cancer, or block antigens that help the cancer grow and spread.
How often is Opdivo given?
The amount of infusions you need depends on: Most patients receive an infusion of Opdivo at an outpatient treatment center every 2 weeks for about a month. Each infusion is given intravenously over 30 minutes. Opdivo is fairly new, having been approved by the FDA in 2015.
How much does Opdivo cost?
Opdivo is considered a specialty medication in both its brand name and generic forms. Depending on the dose, Opdivo can cost $6,580 per infusion. According to the manufacturer, more than 60 percent of patients pay only a quarter of this price or less with coverage from Medicare, Medicaid, or other insurance plans.
What is Opdivo used for?
Opdivo (nivolumab) is a prescription immunotherapy medication that treats certain forms of cancer and is given intravenously. It can be used alone or in combination with another medication called Yervoy (ipilimumab) plus chemotherapy. Opdivo is used as the first choice treatment for people with advanced small cell lung cancer.
What is Opdivo treatment?
About Opdivo. Takeaway. Opdivo (nivolumab) is an immunotherapy cancer treatment for advanced lung cancer and certain resistant cancers. Medicare covers cancer treatment under parts A, B, and C, depending on which phase of treatment you’re in, where you receive treatment, and the plan you have. If you have original Medicare ...
What is a Medigap plan?
Medicare supplemental insurance, or Medigap coverage, is an optional plan that can be used to help cover your share of your Medicare costs, such as out-of-pocket expenses or copayments. If you have costs left over from your Part A or Part B coverage of Opdivo, a Medigap plan may be able to help.
How much does Medicare Part B pay?
With Medicare Part B, you’ll pay 20 percent of the medication’s cost after you’ve met your deductible. If you have a Medigap plan, you can offset your share of the medication cost even more. If you have Medicare Part C, your cost will depend on your plan coverage and your out-of-pocket maximum.
How much does Medicare pay for infusions?
People with Medicare can expect to pay between $0 and $8,210 per infusion. The out-of-pocket cost for about half of the infusions given is $25 or less. However, what you pay depends on your specific Medicare coverage.
What is OPDIVO used for?from opdivohcp.com
OPDIVO is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT). OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment ...
What is opdivo nivolumab?from opdivohcp.com
OPDIVO ® (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
What is odivo in cancer?from opdivohcp.com
OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
What is the name of the drug that is used to treat pleural mesothelioma?from opdivohcp.com
OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).
Can opdivo cause fetal harm?from opdivohcp.com
Based on its mechanism of action and findings from animal studies, OPDIVO and YERVOY can cause fetal harm when administered to a pregnant woman. The effects of YERVOY are likely to be greater during the second and third trimesters of pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with OPDIVO and YERVOY and for at least 5 months after the last dose.
Can OPDivo cause thyroid problems?from opdivohcp.com
OPDIVO and YERVOY can cause primary or secondary adrenal insufficiency, immune-mediated hypophysitis, immune-mediated thyroid disorders, and Type 1 diabetes mellitus, which can present with diabetic ketoacidosis. Withhold OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism; initiate hormone replacement as clinically indicated. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism; initiate hormone replacement or medical management as clinically indicated. Monitor patients for hyperglycemia or other signs and symptoms of diabetes; initiate treatment with insulin as clinically indicated.
Does opdivo cause liver toxicity?from opdivohcp.com
OPDIVO in combination with cabozantinib can cause hepatic toxicity with higher frequencies of Grade 3 and 4 ALT and AST elevations compared to OPDIVO alone. Consider more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents. In patients receiving OPDIVO and cabozantinib, Grades 3 and 4 increased ALT or AST were seen in 11% of patients.
What is OPDIVO in combination with?
OPDIVO, in combination with YERVOY ® (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic melanoma.
What is OPDIVO used for?
OPDIVO is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT). OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment ...
What is odivo in cancer?
OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
What is opdivo nivolumab?
OPDIVO ® (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
What is the name of the drug that is used to treat pleural mesothelioma?
OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).
Does opdivo cause liver toxicity?
OPDIVO in combination with cabozantinib can cause hepatic toxicity with higher frequencies of Grade 3 and 4 ALT and AST elevations compared to OPDIVO alone. Consider more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents. In patients receiving OPDIVO and cabozantinib, Grades 3 and 4 increased ALT or AST were seen in 11% of patients.
Is opdivo a single agent?
OPDIVO ® (nivolumab), as a single agent, is indicated for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
What is OPDIVO used for?from opdivohcp.com
OPDIVO is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT). OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment ...
What is opdivo nivolumab?from opdivohcp.com
OPDIVO ® (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
What is odivo in cancer?from opdivohcp.com
OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
What is the name of the drug that is used to treat pleural mesothelioma?from opdivohcp.com
OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).
Can opdivo cause fetal harm?from opdivohcp.com
Based on its mechanism of action and findings from animal studies, OPDIVO and YERVOY can cause fetal harm when administered to a pregnant woman. The effects of YERVOY are likely to be greater during the second and third trimesters of pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with OPDIVO and YERVOY and for at least 5 months after the last dose.
Can OPDivo cause thyroid problems?from opdivohcp.com
OPDIVO and YERVOY can cause primary or secondary adrenal insufficiency, immune-mediated hypophysitis, immune-mediated thyroid disorders, and Type 1 diabetes mellitus, which can present with diabetic ketoacidosis. Withhold OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism; initiate hormone replacement as clinically indicated. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism; initiate hormone replacement or medical management as clinically indicated. Monitor patients for hyperglycemia or other signs and symptoms of diabetes; initiate treatment with insulin as clinically indicated.
Does opdivo cause liver toxicity?from opdivohcp.com
OPDIVO in combination with cabozantinib can cause hepatic toxicity with higher frequencies of Grade 3 and 4 ALT and AST elevations compared to OPDIVO alone. Consider more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents. In patients receiving OPDIVO and cabozantinib, Grades 3 and 4 increased ALT or AST were seen in 11% of patients.
What is opdivo used for?
OPDIVO ® (nivolumab) is a prescription medicine used to treat people with cancer of the stomach (gastric), cancer where the esophagus joins the stomach (gastroesophageal junction), and in people with esophageal adenocarcinoma. OPDIVO may be used in combination with chemotherapy that contains fluoropyrimidine and platinum when your cancer cannot be ...
What is the name of the medicine that is used to treat pleural mesothelioma?
For adults newly diagnosed with malignant pleural mesothelioma (MPM) OPDIVO ® (nivolumab) is a prescription medicine used in combination with YERVOY ® (ipilimumab) as a first treatment for adults with a type of cancer that affects the lining of the lungs and chest wall called malignant pleural mesothelioma which cannot be removed by surgery.
Does opdivo work for bladder cancer?
For people with previously treated advanced bladder cancer (urothelial carcinoma) OPDIVO ® (nivolumab) is a prescription medicine used to treat people with bladder cancer (urothelial carcinoma) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working.
Is opdivo a prescription?
There is ongoing evaluation of clinical benefit of OPDIVO for this use. OPDIVO ® (nivolumab) is a prescription medicine used in combination with YERVOY ® (ipilimumab) to treat people with liver cancer (hepatocellular carcinoma) if you have previously received treatment with sorafenib.
Does opdivo work?
OPDIVO ® (nivolumab) is a prescription medicine used to treat people with a type of advanced stage lung cancer (called non-small cell lung cancer) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working.
Is OPDivo safe for children?
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with MSI-H or dMMR metastatic colorectal cancer, or in children younger than 18 years of age for the treatment of any other cancers. OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous. (IV) use.
What is opdivo used for?from opdivo.com
OPDIVO ® (nivolumab) is a prescription medicine used to treat people with cancer of the stomach (gastric), cancer where the esophagus joins the stomach (gastroesophageal junction), and in people with esophageal adenocarcinoma. OPDIVO may be used in combination with chemotherapy that contains fluoropyrimidine and platinum when your cancer cannot be ...
What is the name of the medicine that is used to treat pleural mesothelioma?from opdivo.com
For adults newly diagnosed with malignant pleural mesothelioma (MPM) OPDIVO ® (nivolumab) is a prescription medicine used in combination with YERVOY ® (ipilimumab) as a first treatment for adults with a type of cancer that affects the lining of the lungs and chest wall called malignant pleural mesothelioma which cannot be removed by surgery.
Can OPDIVO harm your baby?from opdivo.com
are pregnant or plan to become pregnant. OPDIVO and YERVOY can harm your unborn baby.
Does opdivo work for bladder cancer?from opdivo.com
For people with previously treated advanced bladder cancer (urothelial carcinoma) OPDIVO ® (nivolumab) is a prescription medicine used to treat people with bladder cancer (urothelial carcinoma) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working.
Is opdivo a prescription?from opdivo.com
There is ongoing evaluation of clinical benefit of OPDIVO for this use. OPDIVO ® (nivolumab) is a prescription medicine used in combination with YERVOY ® (ipilimumab) to treat people with liver cancer (hepatocellular carcinoma) if you have previously received treatment with sorafenib.
Can a patient sign a patient authorization form?from bmsaccesssupport.bmscustomerconnect.com
A completed form requires signatures from both physician AND patient. For convenience, patients can sign their Patient Authorization and Agreement Form electronically by clicking here.
Available medicines
Find out if the medicine your doctor prescribed is available through the Bristol Myers Squibb Patient Assistance Foundation.
Eligibility
Complete a brief assessment to see if you might be eligible for assistance.
How to apply
We'll need some information from both you and your doctor to process your application.
